InsiderTrades

Form 4 for IONS IONIS PHARMACEUTICALS INC

Accepted 2026-01-20 00:00:00 ET · period of report 2026-01-15 · accession 0000874015-26-000065 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-01-20 2026-01-16 IONS HOUGEN ELIZABETH L EVP, CFO, Fin S - Sale+OE $75.22 -12.9K 126.3K -9% -$972.0K
D 2026-01-20 2026-01-15 IONS HOUGEN ELIZABETH L EVP, CFO, Fin M - OptEx $0.00 +28.7K 139.2K +26% $0
DM 2026-01-20 2026-01-15 IONS HOUGEN ELIZABETH L EVP, CFO, Fin A - Grant $0.00 +47.2K 68.8K +219% $0
D 2026-01-20 2026-01-15 IONS HOUGEN ELIZABETH L EVP, CFO, Fin M - OptEx $0.00 -28.7K 55.9K -34% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-01-16 S D 12,922 $75.22 126,307 D — — (F2) The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.18 to $75.26 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
2 Common Common Stock 2026-01-15 M A 28,729 $0.00 139,229 D — — (F1) Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
3 Derivative Performance Restricted Stock Units 2026-01-15 A A 34,360 $0.00 120,995 D $0.00 · 2029-01-15 to — 34,360 Common Stock (F4) Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. (F5) The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
4 Derivative Restricted Stock Unit 2026-01-15 A A 12,885 $0.00 68,825 D $0.00 · 2027-01-15 to — 12,885 Common Stock (F8) Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. (F6) Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. (F7) Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
5 Derivative Restricted Stock Unit 2026-01-15 M D 28,729 $0.00 55,940 D $0.00 · 2026-01-15 to — 28,729 Common Stock (F6) Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. (F7) Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.